Skip to main content
. Author manuscript; available in PMC: 2019 Mar 21.
Published in final edited form as: Cell Chem Biol. 2017 Nov 9;25(1):88–99.e6. doi: 10.1016/j.chembiol.2017.10.005

Figure 3. Western blotting validation of multi-kinase degradation induced by TL12-186, a CRBN-mediated proteosome-dependent process.

Figure 3.

(A) Immunoblots for PTK2B, AURKA, BTK, FLT3 and GAPDH in MOLM-14 cells after 4-hour treatment of DMSO, pomalidomide, TL13-87, TL12-186 or TL13-27 at indicated concentrations. See also Figure S2A.

(B) Immunoblots for PTK2B, AURKA, BTK, FLT3 and GAPDH in MOLM-14 cells pre-treated with DMSO, carfilzomib, MLN4924 or pomalidomide for 4 hours, followed by 4-hour co-treatment with DMSO or TL12-186. See also Figure S2B.

(C) Immunoblots for PTK2B, AURKA, BTK, FLT3, GAPDH and CRBN in WT and CRBN−/− MOLM-14 cells after 4-hour treatment with DMSO or TL12-186. See also Figure S2C.

(D) Immunoblots for PTK2B, AURKA, ITK, WEE1 and GAPDH in MOLT-4 cells after the same treatment regimen described in (A). See also Figure S2D.

(E) Immunoblots for PTK2B, AURKA, ITK, WEE1 and GAPDH in MOLT-4 cells after the same treatment regimen described in (B). See also Figure S2E.

(F) Immunoblots for PTK2B, AURKA, ITK, WEE1, GAPDH and CRBN in WT and CRBN−/− MOLT-4 cells after 4-hour treatment with DMSO or TL12-186. See also Figure S2F.